Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM52PE | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14811.203 | 0.3514 | -0.2893 | 1.0107 | |
| SUM52PE | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14811.203 | 0.3514 | -0.2893 | 1.0107 | |
| SUM52PE | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14811.203 | 0.3117 | -0.3690 | 1.0107 | |
| SUM52PE | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14811.203 | 0.3117 | -0.3690 | 1.0107 | |
| SUM52PE | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14811.203 | 0.2585 | -0.4756 | 1.0107 | |
| SUM52PE | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14811.203 | 0.2585 | -0.4756 | 1.0107 | |
| SUM52PE | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14811.203 | 0.2437 | -0.5052 | 1.0107 | |
| SUM52PE | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14811.203 | 0.2437 | -0.5052 | 1.0107 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7542.074 | 0.9734 | 0.9637 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7542.074 | 0.9734 | 0.9637 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7542.074 | 0.9080 | 0.8726 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7542.074 | 0.9080 | 0.8726 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7542.074 | 1.0073 | 1.0099 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7542.074 | 1.0073 | 1.0099 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7542.074 | 0.7473 | 0.6399 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7542.074 | 0.7473 | 0.6399 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7542.074 | 0.0142 | -0.8900 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7542.074 | 0.0142 | -0.8900 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7542.074 | 0.0069 | -0.9330 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7542.074 | 0.0069 | -0.9330 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7542.074 | 0.0034 | -0.9587 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7542.074 | 0.0034 | -0.9587 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7542.074 | 0.0081 | -0.9251 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7542.074 | 0.0081 | -0.9251 | 1.4673 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7542.074 | 0.0081 | -0.9251 | 1.4673 |